These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-004465-15 A multicentre, open, prospective study investigating clinical efficacy, safety, and pharmacokinetic properties of the human normal immunoglobulin for intravenous administration BT681 in patients with ... 2008-04-30 due-trials
Reported results 2005-003737-40 An open, prospective, randomised parallel study investigating efficacy and safety of the human hepatitis B immunoglobulin BT088 after subcutaneous or intramuscular application in liver transplanted pa... 2008-03-03 due-trials
Reported results 2005-004918-32 A monocentre, open-label, prospective study investigating the effects of the human normal immunoglobulin Intratect®/ BT 681 for intravenous administration on clinical efficacy, safety, and laboratory ... 2008-10-31 due-trials
Completed, but no date, and reported results 2006-000110-21 An open, randomised parallel study investigating efficacy and safety of the human hepatitis B immunoglobulin BT088 after subcutaneous or intramuscular application for perinatal prophylaxis in infants ... bad-data
Reported results 2007-004692-19 Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus during pregnancy. A randomised, open, controlled, prospective, multicentre and multinational stud... 2016-12-22 due-trials
Reported results 2008-001241-26 A randomized, placebo-controlled, double-blind, dose escalation study to evaluate the efficacy, safety and tolerability of the study drug BT971 in patients with rheumatoid arthritis receiving concomit... 2011-04-01 due-trials
Reported results 2008-007458-37 A randomized, placebo-controlled, double-blind, multicentre, multiple dose, cohort study with escalating doses to evaluate the safety and efficacy of the humanized monoclonal antibody (mab) BT061 admi... 2011-05-24 due-trials
Completed, but no date, and reported results Terminated 2008-007625-39 An open, prospective, single-arm study investigating safety and efficacy of the human hepatitis B immunoglobulin BT088 after subcutaneous application in liver transplanted patients Clinical Phase: III bad-data
Reported results 2010-018485-24 A multi-center, double-blind, randomized, placebo-controlled, dose-finding study in patients with active rheumatoid arthritis incompletely controlled on stable MTX doses to investigate efficacy and sa... 2013-10-16 due-trials
Reported results 2010-019249-25 An open, prospective trial investigating pharmacokinetics and safety (Part A) of the human normal immunoglobulin for intravenous infusion (IVIG) BT090 and tolerability and safety of escalating infusio... 2012-01-20 due-trials
Reported results 2010-022380-35 A randomized, double-blind, placebo-controlled, multicenter, parallel-group, adaptive group-sequential phase II study, to determine the efficacy and safety of BT086 as an adjunctive treatment in sever... 2015-02-25 due-trials
Reported results 2011-004154-25 A prospective, open-label, phase I/II study investigating pharmacokinetic properties of BT524 and efficacy and safety of BT524 in the treatment and prophylaxis of bleeding in patients with congenital ... 2020-05-15 due-trials
Reported results 2012-002516-51 An open, prospective, single arm study investigating efficacy and safety of human hepatitis B immunoglobulin Zutectra in liver transplanted patients - the ZEUS Study Studio in aperto, prospettico, ... 2014-11-21 due-trials
Reported results 2013-000114-38 A 24-week phase IIb, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of tregalizumab (BT061) in combination with methotrexate in the treatment of... 2015-06-25 due-trials
Exempt, with results 2013-003252-20 An open-label, two-stage Phase I/IIa dose escalation study of BT062 in metastatic triple receptor-negative breast cancer and in metastatic transitional cell carcinoma of the urinary bladder Eine ... 2017-08-04 not-yet-due
Reported results 2014-005526-35 A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated dose, Multicentre Phase IIa Proof-of-Concept Study with BT063 in Subjects with Systemic Lupus Erythematosus (BT063 in SLE) 2017-10-25 due-trials
Reported results 2015-003652-52 An open label, prospective, multicenter study investigating clinical efficacy, safety, and pharmacokinetic properties of the human normal immunoglobulin for intravenous administration BT595 as replace... 2020-04-01 due-trials
Reported results 2015-003653-17 An open label, prospective, randomized, multicenter study investigating clinical efficacy and safety of the human normal immunoglobulin for intravenous administration BT595 in patients with chronic pr... 2018-12-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-001163-20 A randomized, active-controlled, multicenter, phase III study investigating efficacy and safety of intra-operative use of BT524 (human fibrinogen concentrate) in subjects undergoing major spinal or ab... 2023-11-21 bad-data
Reported results 2020-002345-42 A randomized, placebo controlled, double-blind, multi-center, phase II trial investigating the efficacy and safety of trimodulin (BT588) as add-on therapy to standard of care in adult subjects with se... 2021-06-29 due-trials
Ongoing 2020-002383-32 Prevention of maternal-fetal Cytomegalovirus transmission after primary maternal infection with gestational age ≤ 14 weeks – an open-label, single-arm, prospective trial investigating efficacy and saf... not-yet-due
Ongoing 2022-000736-37 A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects CAP including COVID-19 pneumonia. not-yet-due